Response and Beacon will market screening tests:
This article was originally published in Clinica
Response Biomedical and Beacon Diagnostics will develop, distribute and co-market the portfolio of saliva- and urine-based cancer screening tests being developed by Beacon, using Centocor tumour markers (see Clinica No 740, p 16). Beacon will use Response's Rapid Analyte Measurement Platform (RAMP) technology, which offers the possibility of point-of-care tests with the accuracy of those from laboratory-based analysers.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.